Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib
Savolitinib is a highly selective mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor (TKI). Based on its significant efficacy shown in clinical studies, savolitinib was conditionally approved for marketing in China on 22 June 2021, for the treatment of advanced non-small cell lung can...
Main Authors: | Li Zhang, Yongsheng Wang, Lizhu Lin, Yongfeng Yu, Shun Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-12-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359231216089 |
Similar Items
-
The protocol for the consensuses of Chinese experts on glioma multidisciplinary team management
by: The National Glioma MDT Alliance National Center for Neurological Disorders, et al.
Published: (2022-01-01) -
Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib
by: Qing ZHOU, et al.
Published: (2022-08-01) -
Corrigendum: The protocol for the consensuses of Chinese experts on glioma multidisciplinary team management
Published: (2023-01-01) -
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
by: Wenxian Wang, et al.
Published: (2022-12-01) -
Multidisciplinary experts consensus for assessment and management of vestibular migraine
by: Stroke and Vertigo Association of Chinese Stroke Association, et al.
Published: (2019-01-01)